标题
Gene therapies: the challenge of super-high-cost treatments and how to pay for them
作者
关键词
-
出版物
Regenerative Medicine
Volume 11, Issue 4, Pages 381-393
出版商
Future Medicine Ltd
发表日期
2016-05-17
DOI
10.2217/rme-2016-0010
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Glybera's Second Act: The Curtain Rises on the High Cost of Therapy
- (2015) Seppo Ylä-Herttuala MOLECULAR THERAPY
- The payers' perspective on gene therapies
- (2015) Nicolas Touchot et al. NATURE BIOTECHNOLOGY
- Compassionate use of orphan drugs
- (2015) Hanna I. Hyry et al. Orphanet Journal of Rare Diseases
- Bringing regenerative medicines to the clinic: the future for regulation and reimbursement
- (2015) Tania Bubela et al. Regenerative Medicine
- Delayed access to treatments for rare diseases: Who's to blame?
- (2015) Karen Feltmate et al. RESPIROLOGY
- Evaluating Global Early Market Access Opportunities For Innovative Therapies: Focus On Japan, Uk And Us
- (2015) D.R. Carr et al. VALUE IN HEALTH
- Do the Current Performance-Based Schemes in Italy Really Work? “Success Fee”: A Novel Measure for Cost-Containment of Drug Expenditure
- (2015) Andrea Navarria et al. VALUE IN HEALTH
- The special case of gene therapy pricing
- (2014) Troyen A Brennan et al. NATURE BIOTECHNOLOGY
- Shining a light in the black box of orphan drug pricing
- (2014) Eline Picavet et al. Orphanet Journal of Rare Diseases
- Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
- (2014) Mike Paulden et al. PHARMACOECONOMICS
- Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa
- (2013) Lara Cutlar et al. EXPERIMENTAL DERMATOLOGY
- Pricing for Orphan Drugs
- (2013) Brian P. O’Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Regulatory evaluation of Glybera in Europe — two committees, one mission
- (2013) Daniela Melchiorri et al. NATURE REVIEWS DRUG DISCOVERY
- The Impact of Indication Extensions on Pharmaceutical Prices
- (2013) C. Genane et al. VALUE IN HEALTH
- Characterizing Disease Burden in an Ultra-Rare Disease in the United States: Transthyretin (TTR) Amyloidosis Patients & Caregivers
- (2013) M. Stewart et al. VALUE IN HEALTH
- The need for worldwide policy and action plans for rare diseases
- (2012) John Forman et al. ACTA PAEDIATRICA
- What Is Wrong with Orphan Drug Policies? Suggestions for Ways Forward
- (2012) Panos Kanavos et al. VALUE IN HEALTH
- Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
- (2011) Szymon Jarosławski et al. BMC HEALTH SERVICES RESEARCH
- Pricing and reimbursement of orphan drugs: the need for more transparency
- (2011) Steven Simoens Orphanet Journal of Rare Diseases
- PHP6 QUANTITATIVE ANALYSIS OF THE INFLUENCE OF DISEASE AND PRODUCT CHARACTERISTICS ON ORPHAN DRUG PRICES IN EUROPE
- (2011) S Aballea et al. VALUE IN HEALTH
- Inherited epidermolysis bullosa
- (2010) Jo-David Fine Orphanet Journal of Rare Diseases
- Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe
- (2010) Alain Denis et al. Applied Health Economics and Health Policy
- The prevalence of cystic fibrosis in the European Union
- (2008) Philip M. Farrell Journal of Cystic Fibrosis
- Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006
- (2008) Jo-David Fine et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More